DelSiTech Ltd is attending the 3rd GLP‑1 Based Therapeutics Summit, held on 14–16 April 2026 in Boston, MA, USA.
The summit brings together biopharma and biotech leaders to discuss next‑generation GLP‑1‑based therapies for obesity and cardiometabolic diseases.
DelSiTech will participate in discussions on innovative long‑acting drug delivery solutions supporting differentiated incretin‑based therapies, including ultra‑long‑acting GLP‑1 and amylin analogues.
DelSiTech will be represented by Business Development Manager Milla Runsala. Reach out here to book a meeting or connect via LinkedIn.